OTCMKTS:HBPCF Helix Biopharma (HBPCF) Stock Price, News & Analysis $1.71 0.00 (0.00%) As of 09/18/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartEarnings About Helix Biopharma Stock (OTCMKTS:HBPCF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Helix Biopharma alerts:Sign Up Key Stats Today's Range$1.71▼$1.7150-Day Range$1.71▼$1.7152-Week Range$1.71▼$1.73VolumeN/AAverage VolumeN/AMarket Capitalization$130.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Helix BioPharma Corp. is a Canadian biotechnology company focused on developing novel therapies for cancer. Its research has centered on targeted treatments intended to address the tumor microenvironment and improve the delivery or effectiveness of anticancer agents. The company’s principal investigational product has been L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6, a protein expressed on the surface of certain cancer cells. The treatment is intended to alter the acidic conditions surrounding tumors, which may help create an environment less favorable to cancer-cell growth. Helix has investigated L-DOS47 in cancers including pancreatic cancer and non-small cell lung cancer. Helix BioPharma is headquartered in Canada and has conducted its drug-development activities through international clinical and research programs. As a clinical-stage biotechnology company, its products have primarily remained in development rather than being marketed as commercially available medicines.AI Generated. May Contain Errors. Read More Receive HBPCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Helix Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HBPCF Stock News HeadlinesHelix BioPharma Files Interim Financial Statements for April 2025June 16, 2025 | tipranks.comHelix BioPharma Appoints New CFO to Drive Strategic GrowthJune 2, 2025 | tipranks.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 20 at 1:00 AM | The Oxford Club (Ad)Helix BioPharma Secures $13 Million Financing to Advance Cancer TherapiesMay 14, 2025 | tipranks.comHelix BioPharma Appoints New CEO to Propel Clinical AdvancementsApril 10, 2025 | tipranks.comHelix BioPharma Engages ITG for Market-Making ServicesApril 3, 2025 | tipranks.comHelix BioPharma Corp. Announces Key Decisions from Annual MeetingMarch 26, 2025 | tipranks.comHelix BioPharma Releases Interim Financial Statements for January 2025March 18, 2025 | tipranks.comSee More Headlines HBPCF Stock Analysis - Frequently Asked Questions How have HBPCF shares performed this year? Helix Biopharma's stock was trading at $1.7338 at the beginning of the year. Since then, HBPCF stock has decreased by 1.4% and is now trading at $1.71. How were Helix Biopharma's earnings last quarter? Helix Biopharma Corp. (OTCMKTS:HBPCF) announced its earnings results on Friday, June, 12th. The company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.07. How do I buy shares of Helix Biopharma? Shares of HBPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings6/12/2026Today9/20/2026Next Earnings (Estimated)10/29/2026Fiscal Year End7/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:HBPCF CIKN/A Webwww.helixbiopharma.com Phone905-841-2300Fax905-841-2244Employees9Year Founded1995Profitability EPS (Trailing Twelve Months)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.73 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.61% Return on Assets-17.14% Debt Debt-to-Equity RatioN/A Current Ratio0.45 Quick Ratio0.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book11.40Miscellaneous Outstanding Shares76,380,000Free Float70,573,000Market Cap$130.61 million OptionableNot Optionable Beta0.18 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:HBPCF) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our PartnersMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredNew Form of AI Could Ignite the ‘Great Wealth Rotation’Marc Chaikin, a 60-year Wall Street veteran who worked alongside Paul Tudor Jones and Steve Cohen, says a new ...Chaikin Analytics | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Helix Biopharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Helix Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
